Cooley has advised Outlook Therapeutics. Paul Hastings has advised Piper Sandler, BTIG and Brookline Capital Markets as underwriters. Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company...
Outlook Therapeutics Announces $55 Million Public Offering of Shares and Warrants
FDA Approves Outlook Therapeutics’ Lytenava for Wet Age-Related Macular Degeneration
Hogan Lovells Cadwalader has advised Outlook Therapeutics, Inc. Outlook Therapeutics, Inc. has obtained U.S. Food and Drug Administration (FDA) approval for LYTENAVA™ (bevacizumab-vikg), marking the company’s...


























